These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 34294146)

  • 1. Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment.
    Chen W; Shen L; Jiang J; Zhang L; Zhang Z; Pan J; Ni C; Chen Z
    Biomark Res; 2021 Jul; 9(1):59. PubMed ID: 34294146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining microenvironment normalization strategies to improve cancer immunotherapy.
    Mpekris F; Voutouri C; Baish JW; Duda DG; Munn LL; Stylianopoulos T; Jain RK
    Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3728-3737. PubMed ID: 32015113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
    Fukumura D; Kloepper J; Amoozgar Z; Duda DG; Jain RK
    Nat Rev Clin Oncol; 2018 May; 15(5):325-340. PubMed ID: 29508855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers.
    Shi Y; Li Y; Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Lv C; Han S; Yu Y; Xu F; Tian Y
    Int Immunopharmacol; 2022 Sep; 110():108968. PubMed ID: 35764018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.
    Zheng W; Qian C; Tang Y; Yang C; Zhou Y; Shen P; Chen W; Yu S; Wei Z; Wang A; Lu Y; Zhao Y
    Front Immunol; 2022; 13():1035323. PubMed ID: 36439137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanotherapeutic approaches targeting angiogenesis and immune dysfunction in tumor microenvironment.
    Hameed S; Bhattarai P; Dai Z
    Sci China Life Sci; 2018 Apr; 61(4):380-391. PubMed ID: 29607461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.
    Huang Y; Yuan J; Righi E; Kamoun WS; Ancukiewicz M; Nezivar J; Santosuosso M; Martin JD; Martin MR; Vianello F; Leblanc P; Munn LL; Huang P; Duda DG; Fukumura D; Jain RK; Poznansky MC
    Proc Natl Acad Sci U S A; 2012 Oct; 109(43):17561-6. PubMed ID: 23045683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.
    Tartour E; Pere H; Maillere B; Terme M; Merillon N; Taieb J; Sandoval F; Quintin-Colonna F; Lacerda K; Karadimou A; Badoual C; Tedgui A; Fridman WH; Oudard S
    Cancer Metastasis Rev; 2011 Mar; 30(1):83-95. PubMed ID: 21249423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
    Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T
    Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrogel/nanoparticles-mediated cooperative combination of antiangiogenesis and immunotherapy.
    Yang A; Sheng S; Bai Y; Xing G; Yu X; Zhu D; Mei L; Dong X; Lv F
    Acta Biomater; 2022 Nov; 153():124-138. PubMed ID: 36179979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
    Huang Y; Goel S; Duda DG; Fukumura D; Jain RK
    Cancer Res; 2013 May; 73(10):2943-8. PubMed ID: 23440426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Microenvironment and Nitric Oxide: Concepts and Mechanisms.
    Vedenko A; Panara K; Goldstein G; Ramasamy R; Arora H
    Adv Exp Med Biol; 2020; 1277():143-158. PubMed ID: 33119871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.
    Phuengkham H; Ren L; Shin IW; Lim YT
    Adv Mater; 2019 Aug; 31(34):e1803322. PubMed ID: 30773696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies.
    Melaiu O; Vanni G; Portarena I; Pistolese CA; Anemona L; Pomella S; Bei R; Buonomo OC; Roselli M; Mauriello A; Barillari G
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment.
    Melo V; Bremer E; Martin JD
    Front Cell Dev Biol; 2022; 10():908389. PubMed ID: 35712656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy.
    Zhang Y; Li Y; Chen K; Qian L; Wang P
    Cancer Cell Int; 2021 May; 21(1):262. PubMed ID: 33985527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulation therapy promotes the tumor immune-microenvironment and potentiates the efficacy of immunotherapy by alleviating hypoxia.
    Choi JU; Lee NK; Seo H; Chung SW; Al-Hilal TA; Park SJ; Kweon S; Min N; Kim SK; Ahn S; Kim UI; Park JW; Kang CY; Kim IS; Kim SY; Kim K; Byun Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34341129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy.
    Salemme V; Centonze G; Cavallo F; Defilippi P; Conti L
    Front Oncol; 2021; 11():610303. PubMed ID: 33777750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer.
    Missiaen R; Mazzone M; Bergers G
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):107-116. PubMed ID: 29935312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies.
    Abou Khouzam R; Brodaczewska K; Filipiak A; Zeinelabdin NA; Buart S; Szczylik C; Kieda C; Chouaib S
    Front Immunol; 2020; 11():613114. PubMed ID: 33552076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.